No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Times cited: 5
Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
Times cited: 12
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: A large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
Breast Cancer Research.
Times cited: 40